DescriptionCurator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/22971699; http://www.ncbi.nlm.nih.gov/pubmed/23318685
Curator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/22971699; http://www.ncbi.nlm.nih.gov/pubmed/23318685
Peginesatide (trade name Omontys, formerly Hematide), developed by Affymax and Takeda, is an erythropoietic agent, a functional analog of erythropoietin. It was approved by the U.S. Food and Drug Administration for treatment of anemia associated with chronic kidney disease (CKD) in adult patients on dialysis. Peginesatide is a synthetic peptide, attached to polyethylene glycol ("PEGylated"). It mimics the structure of erythropoietin, the human glycoprotein which promotes red blood cell development. Peginesatide binds to and activates the human erythropoietin receptor and stimulates erythropoiesis in human red cell precursors in vitro.
Originator
Sources: https://www.sec.gov/Archives/edgar/data/1158223/000110465911068407/a11-31307_1ex99d1.htm
Curator's Comment: # Affymax and Takeda Pharmaceutical Company
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P19235 Gene ID: 2057.0 Gene Symbol: EPOR Target Organism: Homo sapiens (Human) |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | OMONTYS Approved UseIndicated for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis. Launch Date2012 |
PubMed
Title | Date | PubMed |
---|---|---|
Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile. | 2009 Nov |
|
Detection of peginesatide in equine serum using liquid chromatography-tandem mass spectrometry for doping control purposes. | 2012 |
|
Lessons learned from peginesatide in the treatment of anemia associated with chronic kidney disease in patients on dialysis. | 2013 |
Patents
Sample Use Guides
Initiate OMONTYS treatment when the hemoglobin level is less than 10 g/dL. The recommended starting dose for the treatment of anemia in patients who are not currently
treated with an ESA is 0.04 mg/kg body weight administered as a single intravenous or subcutaneous injection once monthly.
Route of Administration:
Intravenous
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
ZZ-99
Created by
admin on Fri Dec 15 23:04:29 GMT 2023 , Edited by admin on Fri Dec 15 23:04:29 GMT 2023
|
PRIMARY | |||
|
1248797
Created by
admin on Fri Dec 15 23:04:29 GMT 2023 , Edited by admin on Fri Dec 15 23:04:29 GMT 2023
|
PRIMARY | RxNorm | ||
|
44STI720CW
Created by
admin on Fri Dec 15 23:04:29 GMT 2023 , Edited by admin on Fri Dec 15 23:04:29 GMT 2023
|
PRIMARY | |||
|
DTXSID201027899
Created by
admin on Fri Dec 15 23:04:29 GMT 2023 , Edited by admin on Fri Dec 15 23:04:29 GMT 2023
|
PRIMARY | |||
|
CHEMBL1963684
Created by
admin on Fri Dec 15 23:04:29 GMT 2023 , Edited by admin on Fri Dec 15 23:04:29 GMT 2023
|
PRIMARY | |||
|
1185870-58-9
Created by
admin on Fri Dec 15 23:04:29 GMT 2023 , Edited by admin on Fri Dec 15 23:04:29 GMT 2023
|
PRIMARY | |||
|
DBSALT000136
Created by
admin on Fri Dec 15 23:04:29 GMT 2023 , Edited by admin on Fri Dec 15 23:04:29 GMT 2023
|
PRIMARY | |||
|
C166719
Created by
admin on Fri Dec 15 23:04:29 GMT 2023 , Edited by admin on Fri Dec 15 23:04:29 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD